Management of Hyperkalemia in a Post-Bypass Patient on Eplerenone and Furosemide
For a patient with potassium of 6.0 mEq/L on eplerenone and furosemide, eplerenone should be temporarily discontinued, not just held for 48 hours, until potassium levels normalize below 5.5 mEq/L. 1, 2
Immediate Management Steps
- Discontinue eplerenone immediately as potassium >6.0 mEq/L is considered severe hyperkalemia and requires prompt intervention 1, 3
- Obtain an ECG to assess for hyperkalemia-related changes (peaked T waves, flattened P waves, prolonged PR interval, widened QRS) 1
- Consider hospital admission for monitoring and treatment if ECG changes are present or patient is symptomatic 1
- Recheck potassium and renal function within 24-48 hours 3
- Assess for other contributing factors to hyperkalemia:
Rationale for Discontinuation vs. Holding
- Potassium >6.0 mEq/L represents severe hyperkalemia with increased risk of cardiac arrhythmias and sudden death 1
- FDA labeling for eplerenone states that the drug is contraindicated in patients with serum potassium >5.5 mEq/L 2
- Guidelines recommend discontinuation of aldosterone antagonists when potassium exceeds 5.5 mEq/L 3
- Simply holding the medication for 48 hours may be insufficient as hyperkalemia can persist, especially in patients with renal impairment 3
Monitoring and Follow-up
- Recheck potassium and renal function within 24-48 hours after discontinuing eplerenone 3
- Continue monitoring potassium levels at least weekly until stabilized below 5.5 mEq/L 3
- Consider increasing furosemide dose temporarily to enhance potassium excretion if renal function permits 4
- Counsel patient to avoid high-potassium foods and supplements 3
Considerations for Restarting Eplerenone
- Eplerenone may be restarted only after potassium has normalized to <5.0 mEq/L 2
- When restarting, use a lower dose (12.5 mg daily or every other day) 3
- Monitor potassium within 3-7 days after restarting 3
- Consider whether the benefit of eplerenone outweighs the risk of recurrent hyperkalemia in this patient 5
Common Pitfalls to Avoid
- Failing to discontinue eplerenone with severe hyperkalemia (>6.0 mEq/L) 1, 2
- Inadequate follow-up monitoring after medication changes 3
- Restarting eplerenone too soon or at too high a dose 3
- Not considering other contributing factors to hyperkalemia 3
- Continuing potassium supplements if previously prescribed 3
- Not instructing patients to temporarily stop eplerenone during episodes of dehydration, diarrhea, or when loop diuretic therapy is interrupted 3